TREATMENT OF OBSTRUCTIVE SLEEP APNEA

• US 20040157813A1
• Filed: 02/12/2003
• Published: 08/12/2004
• Est. Priority Date: 11/15/2000
• Status: Active Grant

• Current Assignee: Bjorn Wennerholm, Jim Enkvist
• Original Assignee: Bjorn Wennerholm, Jim Enkvist
• Inventors: Enkvist, Jim, Wennerholm, Bjorn
• Granted Patent: US 6,818,665 B2
• Time in Patent Office: Days
• US Class Current: 514/178
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/4045 Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system

Abstract

The method is for a hormonal treatment to compensate for the weakening of farynx components, tongue, tonsils, uvula, soft palate that occur during deep sleep and blocks the airways to cause obstructive sleep apnea. About 0.5-5 mg of melatonin is orally administered to a person between 10-80 years old before the person sleeps and dehydroepiandrosterone (DHEA) is administered in combination with andrenocorticotropic hormone (ACTH).

Claims

1. A method for hormonal treatment to compensate for weakening of farynx components, tongue, tonsils, uvula, soft palate that occur during deep sleep and blocks the airways to cause obstructive sleep apnea, comprising:

orally administering 0.5-5 mg of melatonin to a person between 10-80 years old before the person sleeps; and

administering dehydroepiandrosterone (DHEA)

2. The method according to claim 1 wherein the method further comprises combining DHEA with an andrenocorticotropic hormone (ACTH) for stimulating DHEA.

3. The method according to claim 1 wherein the method further comprises administering the melatonin at night and DHEA in the mornings.